Puriblood Medical Co., Ltd. (TPEX:6847)
Taiwan
· Delayed Price · Currency is TWD 58.30
+8.60 (17.30%)
Apr 29, 2026, 1:36 PM CST
Puriblood Medical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Revenue | 117.35 | 110.67 | 125.27 | 137.44 | 54.59 | 38.65 | Upgrade
|
| Revenue Growth (YoY) | -7.28% | -11.65% | -8.86% | 151.79% | 41.25% | 1149.06% | Upgrade
|
| Cost of Revenue | 52.85 | 49.52 | 118.75 | 78.78 | 48.99 | 14.27 | Upgrade
|
| Gross Profit | 64.5 | 61.16 | 6.52 | 58.67 | 5.6 | 24.38 | Upgrade
|
| Selling, General & Admin | 33.69 | 32.68 | 30.97 | 28.99 | 20.23 | 12.97 | Upgrade
|
| Research & Development | 30.64 | 31.23 | 25.95 | 22.44 | 20.77 | 14.7 | Upgrade
|
| Operating Expenses | 64.33 | 63.9 | 56.93 | 51.43 | 40.99 | 27.67 | Upgrade
|
| Operating Income | 0.17 | -2.74 | -50.4 | 7.24 | -35.4 | -3.3 | Upgrade
|
| Interest Expense | -0.9 | -0.8 | -1.28 | -1.07 | -0.69 | -1.05 | Upgrade
|
| Interest & Investment Income | 1.49 | 1.88 | 1.95 | 0.58 | 0.07 | 0.01 | Upgrade
|
| Earnings From Equity Investments | -4.7 | -1.06 | -0.96 | -0.13 | -0.07 | -1.53 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.63 | 2.05 | -0.02 | 0.54 | -0.1 | -0.1 | Upgrade
|
| Other Non Operating Income (Expenses) | 5.76 | 1.73 | 0.03 | -0.12 | 0.07 | 2.65 | Upgrade
|
| EBT Excluding Unusual Items | 0.2 | 1.04 | -50.68 | 7.04 | -36.12 | -3.32 | Upgrade
|
| Gain (Loss) on Sale of Investments | -8.62 | -7.03 | -3.75 | 10.05 | -1.9 | 1.13 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.02 | - | -0.15 | - | -0.59 | Upgrade
|
| Pretax Income | -8.42 | -6.01 | -54.43 | 16.94 | -38.02 | -2.78 | Upgrade
|
| Income Tax Expense | -0.95 | -0.64 | -2.83 | 0.41 | - | - | Upgrade
|
| Net Income | -7.47 | -5.37 | -51.6 | 16.53 | -38.02 | -2.78 | Upgrade
|
| Net Income to Common | -7.47 | -5.37 | -51.6 | 16.53 | -38.02 | -2.78 | Upgrade
|
| Shares Outstanding (Basic) | 14 | 14 | 14 | 14 | 12 | 9 | Upgrade
|
| Shares Outstanding (Diluted) | 14 | 14 | 14 | 14 | 12 | 9 | Upgrade
|
| Shares Change (YoY) | - | - | - | 22.10% | 35.52% | - | Upgrade
|
| EPS (Basic) | -0.52 | -0.38 | -3.63 | 1.16 | -3.26 | -0.32 | Upgrade
|
| EPS (Diluted) | -0.53 | -0.38 | -3.63 | 1.16 | -3.26 | -0.32 | Upgrade
|
| Free Cash Flow | -24.82 | -31.74 | 20.4 | -33.04 | -46.83 | -19.47 | Upgrade
|
| Free Cash Flow Per Share | -1.74 | -2.23 | 1.43 | -2.32 | -4.02 | -2.26 | Upgrade
|
| Gross Margin | 54.97% | 55.26% | 5.21% | 42.68% | 10.26% | 63.08% | Upgrade
|
| Operating Margin | 0.14% | -2.48% | -40.24% | 5.27% | -64.84% | -8.53% | Upgrade
|
| Profit Margin | -6.37% | -4.85% | -41.19% | 12.03% | -69.66% | -7.19% | Upgrade
|
| Free Cash Flow Margin | -21.15% | -28.68% | 16.28% | -24.04% | -85.78% | -50.38% | Upgrade
|
| EBITDA | 6.65 | 3.97 | -43.87 | 13.46 | -30.59 | 0.07 | Upgrade
|
| EBITDA Margin | 5.66% | 3.59% | -35.02% | 9.79% | -56.03% | 0.18% | Upgrade
|
| D&A For EBITDA | 6.48 | 6.71 | 6.53 | 6.22 | 4.81 | 3.36 | Upgrade
|
| EBIT | 0.17 | -2.74 | -50.4 | 7.24 | -35.4 | -3.3 | Upgrade
|
| EBIT Margin | 0.14% | -2.48% | -40.24% | 5.27% | -64.84% | -8.53% | Upgrade
|
| Effective Tax Rate | - | - | - | 2.39% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.